Efficacy and safety of anti-CLDN18.2 therapies in advanced or metastatic gastric, gastro-oesophageal junction, and oesophageal carcinomas with CLDN18.2 positivity: a systematic review and meta-analysis

Key Points

• This review aims to evaluate the efficacy and safety of anti-CLDN18.2 therapies in advanced cancers with CLDN18.2 positivity.
• Conducted a systematic review and meta-analysis
• Included studies on anti-CLDN18.2 therapies
• Focused on gastric, gastro-oesophageal junction, and oesophageal carcinomas
• Analyzed therapy efficacy and safety outcomes
• Anti-CLDN18.2 therapies showed positive efficacy in patients with CLDN18.2 positivity
• Safety profiles indicated manageable adverse effects
• Meta-analysis results suggest improved treatment outcomes compared to conventional therapies